Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday.

The shortage of Novo Nordisk’s (NVO) blockbuster weight loss drugs has been resolved, according to the U.S. Food and Drug Administration ...

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

A randomized, placebo-controlled trial validates a side effect frequently observed by doctors and patients. A new study from ...

Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...

A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy ...

Peptide therapy enhances targeted medicine, utilizing specific peptides for effective treatment of cancer, metabolic disorders, and neurodegenerative diseases.

A recent study from the University of Pennsylvania has confirmed that the injectable medication semaglutide can lead to major ...